Study guide

4.2 Extemporaneous Compounding

NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the FPGEE 1.2 How to Use This Study Guide

2 Chapter 2: Foundational Biomedical Sciences I

2.1 Anatomy 2.2 Physiology 2.3 Biochemistry

3 Chapter 3: Foundational Biomedical Sciences II

3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases

4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry

4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions

5 Chapter 5: Pharmacology and Toxicology

5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes

6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics

6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems

7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics

8 Chapter 8: Public Health, Practice Management, and Biostatistics

8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods

9 Chapter 9: Professional Communication and Behavioral Aspects

9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice

10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment

10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education

11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care

11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine

12 Chapter 12: Clinical Sciences III — Evidence-Based Practice

12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability

13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products

13.1 Self-Care and Natural Products

4.2 Extemporaneous Compounding

Key Takeaways Explain This Topic AI

USP General Chapter <795> governs nonsterile compounding, <797> governs sterile compounding, and <800> governs handling of hazardous drugs.

The 2023 USP <797> revision (official Nov 1, 2023) replaced low/medium/high-risk CSP labels with Category 1, Category 2, and Category 3 CSPs plus immediate-use.

Category 1 CSPs are prepared in an SCA (max about 12 hours room temperature / 24 hours refrigerated); Category 2 CSPs require a cleanroom suite and allow longer BUDs based on starting components and storage.

Sterile compounding environments follow ISO 14644-1 classifications: ISO 5 for the PEC, ISO 7 for the buffer area, and ISO 8 for the ante area.

Hazardous drug handling requires a C-PEC (Class II BSC or CACI) inside a C-SEC (negative-pressure buffer with ante), plus CSTDs for administration.

Last updated: July 2026

4.2 Extemporaneous Compounding

Quick Answer: USP <795> governs nonsterile compounding, <797> governs sterile compounding, and <800> governs hazardous drug handling. The 2023 USP <797> revision replaced low/medium/high-risk CSP labels with Category 1, Category 2, and Category 3 — memorize ISO classes, Category BUDs, and alligation/aliquot math.

Compounding is the preparation, mixing, assembling, packaging, and labeling of a customized medication based on a prescription order. The FPGEE tests the three USP chapters that define standards, plus the calculations that translate a prescription into a final product.

USP General Chapter Comparison

  • Feature USP <795> USP <797> USP <800>
  • Scope Nonsterile preparations Sterile preparations (CSPs) Hazardous drug handling

Environment Clean, dedicated area ISO-classified cleanroom suite or segregated compounding area (SCA) Containment primary and secondary engineering controls

Key categories Solid, semi-solid, liquid, suppository Immediate-use; Category 1, 2, and 3 CSPs Receipt, storage, compounding, administering, disposal

BUD default Conservative per current USP <795> table Hours to days (or longer for Category 3 with extra controls) based on environment, starting components, and storage Per <795>/<797> with containment

Reference USP revised; official Nov 1, 2023 USP revised; official Nov 1, 2023 Aligned with the NIOSH hazardous drug list

USP <795> Nonsterile Compounding

<795> covers oral solids, topical preparations, ointments, creams, gels, troches, suppositories, and oral liquids. Key requirements:

Ingredient selection : use USP/NF-grade ingredients; document source, lot, and expiration for each component.

Written procedures (SOPs) for every preparation type and cleaning/garbing process.

Documentation : a Master Formulation Record (MFR) (the recipe) and a Compounding Record (CR) (what was actually done, with signatures).

BUD assignment : defaults are conservative; the 2023 revision sets typical limits such as nonaqueous oral liquids (aw < 0.60) up to 90 days, other nonaqueous dosage forms (aw < 0.60; e.g., capsules, troches, nonaqueous topicals) up to 180 days, non-preserved aqueous dosage forms up to 14 days refrigerated, and preserved aqueous dosage forms up to 35 days. Always confirm against the current USP table.

Common nonsterile dosage forms

Troches/lozenges : polybase or PEG base, molded or compressed; slow buccal dissolution.

Ointments and creams : levigation and geometric dilution; oil-in-water (cream) vs water-in-oil (ointment) systems.

Gels : polymers such as Carbopol (carbomer), HPMC, or Pluronic F-127.

Suspensions : structured vehicle, controlled particle size, suspending agents (e.g., xanthan, Veegum).

Capsules : hand-filled with lactose or starch diluent, often using a capsule machine.

USP <797> Sterile Compounding (2023 Categories)

Sterile compounding requires a controlled environment to prevent microbial, endotoxin, and particulate contamination. The revision that became official on November 1, 2023 retired the old low-, medium-, and high-risk CSP labels and replaced them with Category 1, Category 2, and Category 3 CSPs, plus an immediate-use pathway.

Cleanroom classifications (ISO 14644-1)

  • ISO Class Max particles per cubic meter (>= 0.5 microns) Use
  • ISO 5 <= 3,520 Primary engineering control (PEC): inside the LAFW, BSC, or CAI
  • ISO 7 <= 352,000 Buffer area (cleanroom suite)
  • ISO 8 <= 3,520,000 Ante area / segregation area
  • CSP Categories and Default BUDs

Category Where prepared Core idea Typical maximum BUD (examples)

Immediate-use Point of care; not for storage/batching Urgent need; limited sterile starting ingredients; administration begins promptly <= 4 hours from the start of preparation

Category 1 ISO 5 PEC in an unclassified segregated compounding area (SCA) Shorter BUDs because the surrounding environment is not a full cleanroom suite <= 12 hours controlled room temperature; <= 24 hours refrigerated

Category 2 ISO 5 PEC inside a cleanroom suite (ISO 7 buffer + ISO 8 ante) Longer BUDs; length depends on starting components, aseptic vs terminal sterilization, sterility testing, and storage Example (aseptic, sterile starts, no sterility test): up to 4 days CRT / 10 days refrigerated / 45 days frozen; with nonsterile starts and no sterility test, BUDs are shorter (e.g., 1 day CRT / 4 days refrigerated)

Category 3 Cleanroom suite meeting extra facility, garbing, monitoring, and release-testing requirements Allows the longest BUDs when sterility testing and enhanced controls are met Longer than Category 2 maxima (facility-specific; requires Category 3 compliance)

Exam trap: Do not answer with the retired 2008 labels (low-/medium-/high-risk) as if they were current USP <797> terminology. FPGEE questions after the 2023 revision expect Category 1/2/3 language.

Another trap: For Category 1 and Category 2 CSPs, USP does not allow extending BUDs past the chapter tables merely because a pharmacy has a stability-indicating HPLC assay. Longer dating requires meeting the Category 3 framework (or following an FDA-approved labeling pathway that is not ordinary compounding).

USP <800> Hazardous Drug Handling

<800> applies to all drugs on the NIOSH List of Antineoplastic and Other Hazardous Drugs , which groups hazardous drugs into antineoplastics, non-antineoplastics with reproductive risk, chemicals, endocrine agents, and others.

Engineering controls

C-PEC (Containment Primary Engineering Control): a Class II Biological Safety Cabinet (BSC) or Compounding Aseptic Containment Isolator (CACI), operated inside an ISO 5 environment.

C-SEC (Containment Secondary Engineering Control): an ISO 7 negative-pressure buffer area (typically 0.01 to 0.03 inches water column negative to the ante area) plus an ISO 8 ante area, both externally vented.

PPE and handling

Double chemo-rated gloves and a chemo-rated gown with closed front and cuffs.

Eye and face protection if splash risk exists outside the C-PEC.

Respiratory protection (NIOSH-approved respirator) if handling outside a functioning C-PEC.

Closed-system drug-transfer devices (CSTDs) for compounding and administration.

Spill kits accessible; only trained personnel handle hazardous drugs.

Segregated receipt and dedicated storage with negative pressure and external ventilation; trace chemotherapy waste is segregated and disposed of as hazardous waste.

  • Compounding Calculations
  • Alligation method

Used to mix two strengths to obtain a desired intermediate strength. The differences between the desired strength and each original strength give the parts of the other solution.

Worked example: Prepare 1% hydrocortisone cream from 2.5% and 0.5% strengths.

Parts of 2.5% = 1 - 0.5 = 0.5. Parts of 0.5% = 2.5 - 1 = 1.5. Total = 2.0 parts. Ratio 0.5:1.5 = 1:3 .

For 60 g total: 15 g of 2.5% plus 45 g of 0.5%.

Aliquot method

Used when the drug quantity is too small to weigh accurately on the available balance. Dilute the drug with an inert diluent, weigh a portion of the dilution, and back-calculate the drug mass.

Worked example: Need 5 mg of drug; balance sensitivity is 50 mg. Triturate 100 mg drug with 900 mg lactose to make a 1:10 dilution. Weigh 50 mg of the dilution, which contains 50 mg x (1/10) = 5 mg of drug .

Powder dilution

Use C1 x W1 = C2 x W2 (concentration x weight before = concentration x weight after).

Worked example: Dilute 100 g of 10% powder to 5% strength.

10 x 100 = 5 x W2, so W2 = 200 g. Add 100 g of diluent (e.g., lactose) to the original 100 g.

Beyond-Use Dating and Stability

BUD is not the same as an expiration date. A BUD is the date after which a compounded preparation must not be used; an expiration date is the manufacturer's labeled shelf life of a commercial product. Assign sterile BUDs from the current USP <797> Category tables, and nonsterile BUDs from the current USP <795> table. Stability studies use accelerated conditions (25 degrees C / 60% RH and 40 degrees C / 75% RH) per ICH Q1A, but those studies alone do not override Category 1/2 BUD caps in <797>.

Quality Assurance and Documentation

Master Formulation Record (MFR) : recipe, ingredients, calculations, equipment, and step-by-step procedure.

Compounding Record (CR) : actual lot numbers, quantities weighed, signatures of compounder and verifier.

SOPs for environment, cleaning, garbing, and equipment calibration.

Quality assurance program : environmental sampling (viable air and surface, plus non-viable particle counts), media-fill challenges for sterile compounding personnel, and release testing (sterility and endotoxin) when required for the assigned Category and BUD.

Compounding is high-yield because it blends regulation (USP chapters), math (alligation/aliquot), and patient safety (BUDs, hazardous handling). Memorize the ISO classes, Category 1 vs Category 2 environment distinction, and the C-PEC/C-SEC distinction cold before exam day.